Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Itepekimab AI · 1 trial · 1 indication
Maximum plasma concentration of itepekimab
AUClast: Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast
AUC: Area under the plasma concentration versus time curve extrapolated to infinity
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Itepekimab administered via AI |
| Cohort 2 | ACTIVE_COMPARATOR | Itepekimab administered via PFS |
| Name | Type | Description |
|---|---|---|
| Itepekimab AI | DRUG | Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI |
| Itepekimab PFS | DRUG | Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS |
Inclusion Criteria: • Having given written informed consent prior to undertaking any study-related procedure. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: • Any participant who, in the judgment of the Investigator, is likely to be noncompli...
Itepekimab AI is an investigational small molecule being developed for Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 1 clinical development, meaning it is still being studied and is not yet approved for use. The drug is being evaluated for its safety and pharmacokinetic profile in patients with COPD.
Itepekimab AI is being developed by Sanofi, a global biopharmaceutical company. Sanofi's stock is traded under the ticker symbol SNY. The company is conducting clinical trials to evaluate the drug's potential as a treatment for Chronic Obstructive Pulmonary Disease.
Itepekimab AI is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, and pharmacokinetic properties in patients with Chronic Obstructive Pulmonary Disease.
Itepekimab AI has one completed Phase 1 clinical trial, identified as NCT06114238. This study was a pharmacokinetic comparison of Itepekimab administered via an autoinjector versus a prefilled syringe. The trial enrolled 90 participants in the United States and was active-controlled, though it was not double-blinded.
Itepekimab AI is a small molecule formulation of Itepekimab, which is being developed by Sanofi. The 'AI' designation may refer to a specific formulation or delivery method. The drug is being studied for Chronic Obstructive Pulmonary Disease and is currently in Phase 1 clinical trials.